Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
|
|
- Darrell Logan
- 5 years ago
- Views:
Transcription
1 Supplement to Podiatry Today January 201 Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers Supported by Organogenesis, Inc.
2 Table of Contents Purpose of this Supplement...4 PART 1 Patients with Diabetic Foot Ulcers 1.1 The Challenge of Diabetic Foot Ulcers Pathophysiology of Wound Healing in DFUs Initial Evaluation of Patients with a DFU Estimating the Likelihood of DFU Healing Conventional Wound Therapies Evaluating Response to Conventional Therapy...1 Cover Photo Credit Photo Researchers Picture Number: BH877 Credit: Michele S. Graham / Photo Researchers, Inc License: Rights Managed Images and Text Copyright 2012 Photo Researchers, Inc. All Rights Reserved. 2 Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
3 Table of Contents PART 2 Advanced Therapy of DFUs with Apligraf 2.1 Evidence-Based Selection of Advanced Therapy for DFUs Apligraf: Efficacy and Proposed Mechanism Initiating Apligraf Therapy Evaluating Response to Apligraf & Reapplications Summary...20, LLC HMP Communications, LLC (HMP). All rights reserved. Reproduction in whole or in part prohibited. Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of HMP Communications, the editorial staff, or any member of the editorial advisory board. HMP Communications is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. HMP Communications disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements. Content may not be reproduced in any form without written permission. Reprints of articles are available. Rights, permission, reprint, and translation information is available at: HMP Communications, LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP s products include peer-reviewed and non peer-reviewed medical journals, national tradeshows and conferences, online programs, and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. Discover more about HMP s products and services at Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
4 Purpose of this Supplement Diabetic foot ulcers (DFUs) are one of the most common complications of diabetes mellitus (DM) and are associated with significant morbidity and mortality. Management of DFUs is complex and requires a systematic approach to achieve successful outcomes. The care of DFUs has evolved in recent years as new therapeutic options have become available with varying levels of evidence supporting their use. Education about the latest developments in the evaluation and treatment of DFUs has sometimes not kept up with the pace of this progress, especially with regards to advanced therapies, such as cell therapy, growth factors, negative-pressure therapy, and hyperbaric oxygen therapy. Six experienced wound care specialists reviewed the current status of evidence-based evaluation and therapy of DFUs with a focus on the optimal use of Apligraf, an allogeneic bilayered living-cell-based product that has FDA approval for treatment of DFUs. The objectives of this meeting were two-fold: (1) To highlight key aspects of the evaluation and evidence-based conventional therapy of DFUs (2) To make recommendations regarding the optimal use of Apligraf as evidence-based advanced therapy in the care of DFUs The overarching goal of both these objectives is to empower clinicians caring for patients with DFUs to optimize clinical outcomes by providing an educational resource that is concise and useful in their clinical practices. In this supplement, Part 1 Initial Evaluation of Diabetic Foot Ulcers addresses the first objective and Part 2 Advanced Therapy of DFUs with Apligraf addresses the second objective. Of note, this paper is not intended as an exhaustive review of DFU management. Rather, based on the group discussions during the meeting and the meeting participants extensive clinical experience with DFU management, the intention is to focus on a select number of issues that the group felt was most critical to achieving optimal clinical outcomes in DFU patients. The meeting participants provided a variety of perspectives including academic settings, teaching hospitals, and standalone wound care clinics. Robert Kirsner, MD, PhD, Professor and Vice Chairman of the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine led the group discussions. Following the conference, a first draft summary of the group discussions was written and then extensively edited and finalized utilizing input from all meeting participants. Meeting Participants Dr. Robert S. Kirsner (Moderator) Dr. Kirsner is a tenured professor, Vice Chairman, and holds the endowed Stiefel Laboratories Chair in Dermatology in the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine. He currently serves as director of the University of Miami Hospital Wound Center and chief of Dermatology at the University of Miami Hospital. Dr. Kirsner is also a recently retired board member of the Wound Healing Society and is past president of the Association for the Advancement of Wound Care. He co-directed the Symposium for Advanced wound Care (SAWC) for the past 18 years. In addition to career development awards and industry sponsored funding, he is a recipient of NIH, ACS, CDC funding for his research. Independent of books, book chapters and abstracts, he has published over 50 articles. Dr. Desmond Bell Dr. Desmond Bell is the co-founder and executive director of the Save A Leg, Save A Life Foundation, a multidisciplinary non-profit organization dedicated to the reduction in lower extremity amputations and improving wound healing outcomes through evidence-based methodology and community outreach. He is a board certified wound specialist (CWS/American Board of Wound Management) and has served on their Board of Directors since He serves on the Board of Directors of the Association for the Advancement of Wound Care, the Barbara Bates-Jensen Wound Reach Foundation, the Communications Committee of the Jacksonville Chapter of the American Diabetes Association and the Conference Planning Committee of the Symposium on Advanced Wound Care. He is also a member of the Wound Healing Society and the Vascular Disease Foundation/PAD Coalition. Dr. Bell has been in private practice in Jacksonville, Florida since 1997 and is on staff at Memorial Hospital of Jacksonville, St. Vincent s Medical Center Southside and Specialty Hospital of Jacksonville. 4 Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
5 Dr. Gary Gibbons Dr. Gibbons is medical director for South Shore Hospital Center for Wound Care and Hyperbaric Medicine and Professor of Surgery at the Boston University School of Medicine. Trained as a vascular surgeon, Dr. Gibbons was the first director of the Joslin-Beth Israel Deaconess Foot Center in Boston and his career has centered on diabetic patients with lower extremity wounds, especially those complicated by vascular disease. He has published and spoken extensively on the subject and has been honored with the Pecoraro (ADA), Olmos, and Georgetown Distinguished Achievement awards for his work. Dr. Bill Ennis Dr. Ennis is a professor of clinical surgery and chief of the section of wound healing and tissue repair at the University of Illinois Hospital and Health Sciences System. His active areas of research include healing outcomes measures, microcirculation, macrophage function and the impact of stem cells on wound healing. Dr. Arti Masturzo Dr. Masturzo is a published educator who has dedicated her career to the advancement of wound care best practices and the development of comprehensive wound care programs. She completed her internal medicine residency at the University of Cincinnati and went on to pursue a practice focusing entirely on the care of chronic wounds. She is currently the Medical Director of Comprehensive Wound Programs for Tri- Health Associates, overseeing inpatient and outpatient wound care, including hyperbarics, for multiple hospitals and clinics in greater Cincinnati. In addition, she is the Corporate Director of Medical Affairs of Accelecare Wound Centers. Dr. Masturzo is board-certified in internal medicine and undersea hyperbaric medicine. Dr. Gary Rothenberg Dr. Rothenberg is a board certified podiatrist, certified diabetes educator and certified wound specialist who currently serves as director of resident training and attending podiatrist at the Department of Veteran Affairs Medical Center in Miami, Florida. A graduate of the Ohio College of Podiatric Medicine, he completed years of residency training at the University of Texas Health Science Center in San Antonio. His previous private practice experience and now academic practice have focused on conservative and surgical management of the diabetic foot. Conflicts of Interest Dr. Kirsner indicates advisory board participation with Organogenesis, Shire, Healthpoint, and KCI. Dr. Bell indicates he is a member of the Speaker s Bureau of Organogenesis and Cordis and serves as a consultant with ev, Cook, and Healiance. Dr. Gibbons indicates he is a consultant, speaker, and participates in a clinical experience program for Organogenesis, and that he is principal investigator for a venous leg ulcer study sponsored by Celleration. Dr. Ennis indicates he is a consultant to Organogenesis, KCI, and Accelecare wound centers. Dr. Masturzo indicates she is a member of the Speaker s Bureau of Organogenesis and KCI. She has also served as a consultant to Shire. Dr. Rothenberg indicates he is a member of the Speaker s Bureau for Organogenesis and Healthpoint. Acknowledgements This article is supported by a grant from Organogenesis. The authors would like to thank Ed Perper, MD, and James Radke, PhD, for editorial and manuscript assistance. This supplement is provided as a courtesy to the readers of WOUNDS. This supplement was not subject to the peer review process of WOUNDS. Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers 5
6 PART 1 Patients with Diabetic Foot Ulcers 1.1 The Challenge of Diabetic Foot Ulcers Review of Evidence DFUs are a common complication in patients with DM. The lifetime risk of developing a DFU is 15% to 25% and the prevalence of DFUs among diabetics is 4% to 10%. 1 The morbidity and mortality associated with DFUs is very high. For example, 85% of leg amputations are preceded by DFUs 1 and more than 60% of nontraumatic lower extremity amputations performed in the United States each year occur secondary to complications of DM. 2 Mortality rates following amputation are alarmingly high: up to 40% at 1 year and 80% at 5 years. 1 Unfortunately, DFUs are notoriously difficult to heal. The healing rate even with good standard-of-care treatment is only 1% at 20 weeks (Figure 1). Moreover, DFUs are frequently inadequately managed due to multiple factors including blunted signs of infection, limited understanding of current diagnostic and therapeutic approaches, and insufficient resources. 4 Group Discussion The seriousness of DFUs is often underestimated by both clinicians and patients. A critical first step is for everyone involved to fully understand and explicitly acknowledge that achieving complete healing represents a significant challenge in a high-risk patient. This should motivate both the wound care practitioner and the patient to take all necessary steps to maximize the probability of success. It is important to not underestimate this disease as success is typically harder than many perceive. Educating patients about the challenge of healing their DFU will ideally motivate them to strictly comply with all therapeutic interventions; poor compliance is an important factor that often limits the success of therapy. Importantly, wound care clinicians should understand that even with well-delivered standard care of DFUs, the probability of complete healing is relatively low; therefore from the very start of treatment, clinicians should anticipate that advanced therapy will be required in many patients to achieve complete healing. % Weighted Mean Healing Rate 100% 75% 25% 0% 24.2% 0.9% 12 Weeks 20 Weeks N = 4 trials N = 6 trials Time Elapsed Suggested Reading Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association. Diabetes Care. 1999;22(8): Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;29(2): Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. Diabetes Care. 1999;22(5): Figure 1. Healing rates of control groups from meta-analysis of 10 randomized clinical trials of standard DFU care. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. Diabetes Care. 1999;22(5): Maderal AD, Vivas AC, Zwick TG, Kirsner RS. Diabetic foot ulcers: evaluation and management. Hosp Pract (Minneap). 2012;40(): Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22(): n 6 Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
7 1.2 Pathophysiology of Wound Healing in DFUs Review of Evidence Acute wounds heal through a normal highly regulated process of cell replication, migration, protein synthesis, matrix deposition, and organization. In an acute wound, multiple growth factors, cytokines, and cells including keratinocytes and fibroblasts work in concert to heal the wound completely. 5-7 DFUs are chronic wounds that fail to heal in a regulated and systematic manner due to multiple abnormal physiologic, anatomic, and cellular factors: (1) decreased angiogenic response; (2) neuropathy; () ischemia; (4) endothelial dysfunction; and (5) increased susceptibility to wound infection 5 (Figure 2). In addition, in DFUs there is poor and disorganized regulation of the cytokines, growth factors, proteases, extracellular matrix components, and cells needed to achieve complete wound closure 8,9 : (1) keratinocyte migration and proliferation is impaired 10 ; (2) fibroblast response to growth factors 9 and the ability to synthesize collagen is impaired 11 ; and () there is a relative deficiency of tissue inhibitors of matrix metalloproteinases, which results in degradation of the extracellular matrix. 8,12,1 All these pathophysiologic factors contribute to the poor healing rates observed in patients with DFUs. Group Discussion All wound care practitioners should understand the multiple pathophysiologic defects that contribute to poor healing rates of DFUs. By therapeutically addressing as many of these factors as possible, the likelihood of wound healing can be increased. For example, clinicians must assess and reassess for ischemia, infection, and other factors throughout the course of management that may slow or prevent healing. If healing stalls, some advanced therapies may address the growth factor, cytokine, and cellular abnormalities that interfere with healing of DFUs. Suggested Readings Brem H, Young J, Tomic-Canic M, et al. Clinical efficacy and mechanism of bilayered living human skin equivalent (HSE) in treatment of diabetic foot ulcers. Surg Technol Int. 200;11:2-1. Figure 2. Pathophysiologic factors contributing to poor healing rates of DFUs. Werner S, Krieg T, Smola H. Keratinocyte fibroblast interactions in wound healing. J Invest Dermatol. 2007;127(5): Ghahary A, Ghaffari A. Role of keratinocyte fibroblast cross-talk in development of hypertrophic scar. Wound Repair Regen. 2007;15(suppl 1):S45-S5. n Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers 7
8 1. Initial Evaluation of Patients with a DFU Review of Evidence Several published clinical guidelines exist to assist wound care practitioners with proper evaluation and management of DFUs, including those from the Infectious Diseases Society of America, 14 the American College of Foot and Ankle Surgeons, 15 the Wound Healing Society, 16 and the International Working Group on the Diabetic Foot Editorial Board. 17 Common to these guidelines is the recommendation for a meticulous initial clinical evaluation of every patient with a DFU. Particular attention should be on the following issues: 1) peripheral artery disease; 2) neuropathy; ) nutritional status; 4) wound infection, including osteomyelitis; and 5) hyperglycemia (Figure ). In addition, a wound-specific history must be obtained, including location, duration, inciting event or trauma, previous ulcers and recurrences, hospitalization, previous wound care treatments, off-loading technique, wound response to treatment, patient compliance, family or social problems that are interfering with care, previous foot trauma or surgery, presence of edema, and history of Charcot foot and its treatment. 15 Classification of DFUs is generally predictive of outcomes and may facilitate treatment (Figure 4). The most commonly used classification system is the Wagner system, which divides foot lesions into 6 grades based on the depth of the wound and extent of tissue infection and necrosis. However, the Wagner system does not consider the roles of infection, ischemia, and other factors. The University of Texas San Antonio (UTSA) system associates lesion depth with both ischemia and infection; this system has been validated and is generally predictive of outcome. 15 If possible, the initial evaluation of the DFU should involve a multidisciplinary team that includes wound care professionals and, when indicated, diabetologists or endocrinologists, surgeons (vascular and podiatric), nurses, nutritionists, and pedorthotists. 4 Assess Patient H & P Glycemic control Nutritional evaluation Immune status Neurological evaluation Vascular evaluation Psychosocial evaluation Assess DFU Duration Size (~area in cm 2 Estimate Likelihood of ) Succesful Closure & Depth Discuss with Patient Location Charcot Soft tissue infection & osteomyelitis Consider advanced testing & imaging Appropriate Interventions Standard Therapy for all DFUs Debridement Infection Control Off-Loading Appropriate Dressing Figure. Clinical algorithm for initial assessment of patients with DFUs. Lipsky BA, Berendt AR, Cornia PB, et al Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45(5 Suppl):S1-66. Steed DL, Attinger C, Colaizzi T, et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen. 2006;14(6): Bakker K, Apelqvist J, Schaper NC; International Working Group on Diabetic Foot Editorial Board. Practical guidelines on the management and prevention of the diabetic foot Diabetes Metab Res Rev. 2012;28 Suppl 1: Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
9 Wagner Classification System of DFUs Grade Lesion 0 No open lesions: may have deformity or cellulitis 1 Superficial ulcer 2 Deep ulcer to tendon or joint capsule Deep ulcer with abscess, osteomyelitis, or joint sepsis 4 Local gangrene forefoot or heel 5 Gangrene of entire foot University of Texas Classification System of DFUs Stage A Pre- or post-ulcerative lesions, completely epithelized Grade 0 I II III Superficial wound not involving tendon, capsule, or bone Wound penetrating in tendon or capsule Wound penetrating in bone or joint B Infected Infected Infected Infected C Ischemic Ischemic Ischemic Ischemic D Infected and ischemic Infected and ischemic Infected and ischemic Infected and ischemic Figure 4. Wagner and University of Texas Classification Systems for chronic wounds. Group Discussion Published evidenced-based guidelines should provide a roadmap for care for DFU. Clinicians should follow the recommendations of the published clinical guidelines for initial evaluation of patients with a DFU. Too often inadequate evaluation or treatment of peripheral arterial disease (PAD), or in more severe instances, critical limb ischemia, is a major factor that slows or prevents complete DFU healing. Assessment of vascular status is critical prior to proceeding with other elements of care in patients with a DFU. Another important issue related to the initial evaluation of patients with a DFU is precise baseline measurement of wound size so that the response to treatment can be reassessed quantitatively and accurately (Section 1.6 below: Evaluating Response to Conventional Therapy ). Suggested Reading Lipsky BA, Berendt AR, Cornia PB, et al Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45(5 Suppl):S1-66. Steed DL, Attinger C, Colaizzi T, et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen. 2006;14(6): Bakker K, Apelqvist J, Schaper NC; International Working Group on Diabetic Foot Editorial Board. Practical guidelines on the management and prevention of the diabetic foot Diabetes Metab Res Rev. 2012;28 Suppl 1: Snyder RJ, Kirsner RS, Warriner RA, et al. Consensus recommendations for advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage. 2010;56(suppl 4):S1-S24. Gibbons GW, Shaw PM. Diabetic Vascular Disease: Characteristics of Vascular Disease Unique to the Diabetic Patient. Semin Vasc Surg. 2012;25: n Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers 9
10 1.4 Estimating the Likelihood of DFU Healing Review of Evidence The likelihood of complete DFU healing is determined by multiple factors, both patient-related and wound-related. Important patient-related factors include vascular status, nutritional status, neurologic status, presence and severity of soft tissue infection, osteomyelitis, Charcot, and other factors, including glycemic control. Wound-related factors that have been demonstrated in prospective studies to have predictive value include the size, duration, depth, and grade of the DFU. Larger lesions (>2 cm 2 ), chronic lesions (>6 months - 12 months), deeper lesions, and higher grade lesions are associated with reduced likelihood of complete healing despite continued conventional therapy. Margolis et al 18 pooled data from the standard care arms of 5 clinical trials to determine the effect of wound size and duration on the probability of healing (Figure 5). Healing rates were lower in patients with larger wounds and longer duration wounds. For example, wounds <2 cm 2 and <6 months had a 4% probability of healing at 20 weeks (n = 120 patients) compared to wounds >4 cm 2 and >12 months, which had only a 26% probability of healing (n = 252 patients). Group Discussion Many DFUs heal slowly and many will not heal with standard treatment. Healthcare providers should be keenly aware of the serious challenges involved in treating any DFU successfully. Patients and families must be educated about the poor prognosis for healing in general and the critical importance of strict compliance in order to maximize the probability of success. The studies above clearly show that even in patients with DFUs that are small and of shorter duration, many lesions will not heal with conventional therapy, eg, in the Margolis trial described above, even among patients with small DFUs that were present for less than 6 months more than half (57%) did not heal at 20 weeks. Of course, in larger wounds of greater duration the likelihood of healing is even lower. Therefore, from the first day of treatment onwards, all patients need to understand that DFUs are very difficult to heal with conventional therapy and that most patients will ultimately need to receive evidence-based advanced therapy to maximize their odds of achieving complete healing. In addition, the group believed that in many cases the likelihood of successful healing is overestimated by both clinicians and patients and that greater awareness of the challenges DFUs present may lead to better clinical decisions and higher compliance. Suggested Readings Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol. 2000;16: n 100% % Healed Within 20 Weeks 75% 50% 25% % Healed 0 % <2 2-4 >4 < >12 <2 & <6 >4 & >12 ()*+,#-./0# ()*+,#1*24)+# ()*+,#-./0#+,# Wound Size 1*24)+# & Duration Wound Size cm 2 Wound Duration months cm 2 & months Sample Size: Figure 5. Cumulative healing rates within 20 weeks of care of DFUs. Adapted from Margolis DJ, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol. 2000;16: Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
11 1.5 Conventional Wound Therapies Review of Evidence Management of DFUs is complex and requires a systematic approach to achieve more consistent and successful outcomes. 4 This includes addressing multiple issues: 1) peripheral artery disease; 2) neuropathy; ) nutritional status; 4) ulcer and bone infection; and 5) glycemic control. Detailed discussion of these factors is beyond the scope of this paper. Addressing peripheral artery disease is particularly important. Depending on the population being treated, peripheral ischemia contributes to poor wound healing in 50% to 60% of patients with DFUs. In addition, the wound itself must be treated directly. Below is a brief review of the clinical evidence supporting the administration of conventional wound therapies that are mandated in all patients with DFUs: Before debridement After debridement Offloading. The main mechanism by which DFUs develop is due to increased, sustained and/ or repetitive trauma in the setting of peripheral neuropathy. Distributing and minimizing pressure in the affected area is crucial to achieve healing. Pressure offloading can be achieved with foot inserts, therapeutic shoes, casts, or by surgical procedures. The total-contact cast is considered the gold standard for the management of plantar DFUs as studies have shown the highest healing rates compared with other offloading devices. 19,20 However, it is recognized that limitations to use of total-contact casting exist and alternatives are available which have been shown to be effective. 21,22 Poor patient compliance often limits success of offloading due in part to the fact that these devices limit performance of daily activities and the stability of patients gaits. 2 Therefore, the best device is one with high adherence that best adapts to the patient, permitting continuous use and effective decrease in pressure. Figure 6. Examples of DFUs before and after surgical debridement. Photo credit: Arti B Masturzo MD ABPM/UHM Medical Director Advanced Wound Programs Bethesda North & Good Samaritan Hospitals Cincinnati, OH Debridement. Debridement is considered essential in DFU care although this is supported by data from secondary analyses of controlled trials performed for reasons other than debridement. 24 When undertaken, appropriate debridement includes removal of excess callus and necrotic tissue and likely results in reduction of unresponsive cells in the wound bed and edge, bacterial biofilms and excess matrix metalloproteinases. Among the different types of debridement (surgical, enzymatic, autolytic, mechanical, and biologic), surgical debridement is preferred. (See Figure 6 for examples of DFUs before and after surgical debridement.) Steed et al found topical application of a growth factor with frequent debridement increased the likelihood of healing as did debridement with- Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers 11
12 out growth factor application, but to a lesser extent. 25 The Debridement Performance Index, which evaluates the adequacy of debridement of the wound and wound edges, was found to be an independent factor of wound closure. 26 Finally, it has been suggested that frequent debridement of DFUs may increase wound healing and closure rates, which may be in part due to superior overall care provided to patients. 27 Dressings. Important wound bed preparation principles are moisture balance, minimization of inflammation, infection control, and epithelial edge advancement. The goal is to promote healing via epidermal migration, angiogenesis, and connective tissue synthesis. The type of dressing will be dependent on the wound size, depth, location, the presence of eschar or slough, the amount of exudates, the wound margins, the need for adhesiveness, concern for infection, and conformability. 5 However, there is not enough evidence to suggest that one dressing is more effective than another. Currently, no ideal dressing exists that possesses all properties ideal for all wound types. 4 Group Discussion Standard wound management will succeed in healing only a percentage of DFUs. Unfortunately, optimal standard wound care is not always provided to all patients due to poor adherence to guidelines, diminished compliance, inadequate education of wound care practitioners, lack of close follow-up, insufficient resources, and other factors. Offloading is grossly underutilized, which is unfortunate given the strong evidence supporting its role in promoting wound healing. Practitioners are encouraged to remember that contact-casting is the most strongly supported by clinical evidence and is therefore considered the gold standard. Close follow-up with weekly reassessment is the standard of care; unfortunately, not all practitioners follow this guideline. Early, aggressive, and diligent management of DFUs is not only in the best interest of the patient but is also cost effective since it potentially prevents costly complications. Suggested Readings Brem H, Sheehan P, Boulton AJM. Protocol for treatment of diabetic foot ulcers. Amer J Surg. 2004;187(suppl):1S-10S. Lipsky BA, Berendt AR, Cornia PB, et al Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45(5 Suppl):S1-66. Steed DL, Attinger C, Colaizzi T, et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen. 2006;14(6): Bakker K, Apelqvist J, Schaper NC; International Working Group on Diabetic Foot Editorial Board. Practical guidelines on the management and prevention of the diabetic foot Diabetes Metab Res Rev. 2012;28 (suppl 1): Snyder RJ, Kirsner RS, Warriner RA, et al. Consensus recommendations for advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage. 2010;56(suppl 4):S1-S24.n 12 Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
13 1.6 Evaluating Response to Conventional Therapy Review of Evidence Patients with DFUs should be followed closely with weekly visits. A 2012 study comparing 206 patients with Wagner grade 1 or 2 DFUs who had weekly vs every-other-week visits found that weekly follow-up reduced the median time to wound closure by more than 50% (28 days vs 66 days). 4 Several studies have shown that re-evaluation 4 weeks after initiation of standard wound healing therapy is clinically useful. These studies demonstrate that if wound size has not decreased by at least 50% by the 4th week of treatment, the likelihood of complete wound healing using the same treatment approach is very low For example, in a study of 704 patients, only 18% of DFUs that were not healing adequately at 4 weeks healed at 12 weeks, whereas 58% of DFUs that were healing adequately at 4 weeks did so. 28 In another study, patients with DFUs receiving 4 weeks of conventional therapy whose wounds did not reduce in size by more than 5% had a decreased likelihood of healing at 12 weeks. 0 In addition to percent wound size reduction, Robson et al examined the data from 11 clinical trials and observed that by week 4, the trajectories of the wounds that eventually would heal versus those that did not heal could be differentiated. 1 The Standard Therapy of DFU Reassess DFU within 4 Weeks Wound healing trajectory % area reduction Healing adequately Not healing adequately Follow-up Address factors interfering with healing Ulcer infection Osteomyelitis Ischemia Glycemic control Inadequate offloading Poor nutrition Other factors Complete closure Evidence-based advanced therapy Figure 7. Clinical algorithm for initial assessment of patients with DFUs. Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers 1
14 Wound Healing Society s guidelines recommend a change in treatment if wound size reduction is not observed at 4 weeks of conventional therapy. 16 Group Discussion The evidence in favor of following DFU patients weekly is strong. Once the patient with a DFU is started on standard wound therapies, response to therapy should be re-evaluated at no later than 4 weeks. It is mandatory to perform serial wound size measurements in all cases; but in real-world settings this is not always done. Although a 50% reduction in wound size is desirable and moderately predictive of the likelihood of healing, the overall trajectory of wound healing is most important. Other factors such as initial size, presence of infection, and quality of granulation tissue, in addition to percentage wound size reduction, should be considered in assessing the overall trajectory of wound healing. A suggested algorithm for follow-up evaluation is shown in Figure 7. If the clinician assesses that the wound healing trajectory is inadequate at 4 weeks, reassessment of the wound should be performed and evidence-based advanced therapy should be considered. It is also important to note that the trials described above indicated that a sizeable proportion of patients (42% in one study 0 ) who are healing adequately at 4 weeks will ultimately fail to completely heal; these patients will also require advanced therapy. Suggested Readings Coerper S, Beckert S, Küper MA, Jekov M, Königsrainer A. Fifty percent area reduction after 4 weeks of treatment is a reliable indicator for healing--analysis of a single-center cohort of 704 diabetic patients. J Diabetes Complications. 2009;2:49-5. Margolis DJ, Hoffstad O, Gelfand JM, Berlin JA. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 200;26: Sheehan P, Jones P, Casselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 200;26: Robson MC, Hill DP, Woodske ME, Steed DL. Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Surg. 2000;15(7): n 14 Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
15 PART 2 Advanced Therapy of DFUs with Apligraf 2.1 Evidence-Based Selection of Advanced Therapy for DFUs Review of Evidence In many cases, standard DFU therapy is not sufficient to heal the wound. The appropriate use of advanced therapies in chronic, nonhealing wounds, can prevent limb loss, as well as improve quality of life for patients. 4 The use of advanced therapies is currently included in evidence-based treatment guidelines and algorithms for DFUs. 16 At present there are only three products that are approved by the FDA for treatment of DFUs based on the results of rigorous clinical studies: 1) Apligraf bilayered (fibroblast/keratinocyte) cell-based product 2 2) Dermagraft human-fibroblast-derived dermal substitute ) Regranex platelet-derived growth factor 4 Level 1 RCTs* Highest Level of Evidence Level 2 COHORT StuDies Level Case-Controlled Studies Level 4 Case Series Level 5 Case Report or Expert Opinion Lowest Level of Evidence * RCT = randomized clinical trial Figure 8. The Centre for Evidence-Based Medicine: levels of clinical evidence. Adapted from Centre for Evidence-based Medicine. Accessed August 22, Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers 15
16 The FDA differentiates between wound dressings, which are intended to manage wounds and are classified as non-interactive, and cell-based wound care therapies, which are intended to heal wounds and are classified as interactive. To gain FDA approval for the treatment of DFUs, each of the above products was evaluated in large randomized multicenter clinical trials performed in a DFU patient population. In contrast, many wound dressings and human tissue products receive a 510(K) Clearance, which does not require clinical data and for which even preclinical efficacy studies are typically not performed. 8 The Centre for Evidence-Based Medicine published a Levels of Evidence document to help define a process for determining the value of clinical evidence-based on its source 5 (Figure 8). This pyramid ranks evidence from the highest (Level 1: randomized controlled trials) to the lowest (Level 5: expert opinion or case report). This process provides a guide to clinicians in their decision making to determine the merits of published clinical data. Group Discussion DFUs are a serious complication of DM associated with high morbidity, including limb loss and increased risk of mortality. Practitioners owe it to their patients to utilize the most proven therapies to maximize the likelihood of achieving successful healing, thereby potentially preventing additional complications. This commitment requires using evidence-based therapies that are supported by the highest level of scientific evidence, ie, randomized clinical trials. In real-world settings evidence-based medicine is sometimes delayed or not used as well as it should be. 9 When a patient with a DFU fails to show wound progression with standard care (Section 1.6 above Evaluating Response to Therapy), transition to an evidence-based advanced therapy is appropriate. Three wound healing products have received FDA or postmarketing approval by the FDA for the treatment of DFUs: Apligraf, Dermagraft, and Regranex. Discussion of each of these products is beyond the scope of this paper. The main point here is that when new wound products become available, clinicians should inquire what level of clinical evidence supports their use. In the hierarchy of scientific evidence, randomized clinical trials represent the highest level of evidence while expert opinion and case reports represent the lowest level. Suggested Reading Apligraf [prescribing information]. Canton MA: Organogenesis Inc; December Dermagraft [prescribing information]. Westpoint CT: Advanced Biohealing;2012. Regranex (becaplermin) [prescribing information].fort Worth, TX: Healthpoint Biotherapeutics; Veves A, Falanga V, Armstrong DG, Sabolinski ML, Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2): Marston WA, Hanft J, Norwood P, Pollak R, Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers. Diabetes Care. 200;26(6): Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-bb (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21(5): Centre for Evidence-based Medicine. net/index.aspx?o=1025. Accessed August 22, Maderal AD, Vivas AC, Zwick TG, Kirsner RS. Diabetic foot ulcers: evaluation and management. Hosp Pract (Minneap). 2012;40(): n 16 Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
17 2.2 Apligraf: Efficacy and Proposed Mechanism Review of Evidence Apligraf is a bioengineered allogeneic bilayered living-cellbased product that is FDA-approved for treatment of DFUs of greater than weeks duration. It consists of an epidermal layer of human keratinocytes overlying a dermal layer of human fibroblasts in a collagen matrix. Although the precise mechanism by which Apligraf promotes wound healing is not known, the mechanism of action is believed to be primarily related to its ability to modulate the healing response through the delivery of cytokines and growth factors (Figure 9). Apligraf was evaluated for treatment of DFUs in a randomized controlled trial by Veves et al 6 in which patients with chronic neuropathic DFUs (plantar, medial and lateral aspects of the foot) were randomized to receive up to 5 weekly applications of Apligraf (n=112) plus standard care or standard care alone (n=96). Standard care consisted of saline moistened gauze, wound debridement and offloading. Patients in the Apligraf group had higher rates of complete healing than those in the control group by 12 weeks (56% Apligraf, 8% control, P=0.0042). In addition, the median time to complete closure was reduced in the Apligraf group (65 days vs 90 days, P=0.0026). Similar results were observed in a second randomized controlled trial by Edmonds et al, 7 a multicenter randomized controlled trial in which patients with DFUs received Apligraf (n=) or standard wound care (n=9). While this study was terminated prematurely for non-scientific reasons, at 12 weeks twice as many Apligraf subjects had achieved complete wound closure compared to conventional therapy subjects (52% vs 26%, P=0.049). Rates of adverse events were similar in the Apligraf and control groups in both of these trials. Group Discussion Use of Apligraf as an advanced treatment for DFUs is supported by two randomized clinical trials, which provides a high level of evidence for its use. Overall healing rates and the time to complete healing were substantially improved compared to standard wound therapy. From a pathophysiologic standpoint, this clinical response is understandable since Apligraf provides the cells (fibroblasts and keratinocytes), growth factors, and cytokines that are believed to play important roles in wound healing. Suggested Readings Apligraf [prescription information]. Canton MA: Organogenesis Inc; December Veves A, Falanga V, Armstrong DG, Sabolinski ML, Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2): Edmonds M; European and Australian Apligraf Diabetic Foot Ulcer Study Group. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009;8(1): Kirsner RS. The science of bilayer cell therapy. Wounds (suppl):6-9. n Function 1 Angiogenesis Growth, development, and differentiation Inflammation Proliferation Growth Factor or Cytokine* PDGF-A PDGF-B VEGF IGF-1 IGF-2 TGF-ß1 TGF-ß IL-1a IL-6 IL-8 IL-11 FGF-1 FGF-2 FGF-7 TGF-a Human 2 Human 2 Apligraf 2 Keratinocytes Fibroblasts *As measured by mrna levels Cells were grown in monolayer cultures Cytokines and growth factors were also detected using enzyme-linked immunosorbent assay. 1 Barrientos S, et al. Wound Repair Regen. 2008;16: Brem H, et al. Surg Technol Int. 200;11:2-1 Figure 9. Growth factors and cytokines identified in human keratinocytes, human fibroblasts, and Apligraf. Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers 17
18 2. Initiating Apligraf Therapy Review of Evidence The technique used to apply various wound therapies, including Apligraf, varies among different practitioners. However, since the goal of evidence-based therapy is to replicate the results of clinical studies in real-world clinical care, below is a summary of selected study entry criteria and application techniques employed in the 2 randomized controlled trials of Apligraf: Veves et al study (2001). 6 Study patients included patients with a full-thickness neuropathic DFU on the plantar, lateral or medial surface of the foot of weeks duration and a post-debridement ulcer size between 1 and 16 cm 2 ; without signs of clinical infection at the ulcer site or active Charcot s disease; and, with a good vascular supply as indicated by an audible dorsalis pedis and posterior tibialis pulses and ABI >0.65. The ulcer was debrided and irrigated with saline prior to initial application of Apligraf, which was placed directly over the ulcer site. Any excess edge was trimmed to fit the ulcer. The site was covered with a saline moistened non-adherent primary dressing (Tegapore) and secured with hypoallergenic tape. The wound was then covered with a layer of dry gauze, a layer of petrolatum gauze, and Kling. Edmonds et al study (2009). 7 Study patients had a full-thickness DFU of at least 4 weeks duration; with a surface area between 1 and 16 cm 2 ; limited to the plantar forefoot region; with no signs of infection; and, with an adequate vascular supply to the target extremity. All patients received standard care therapies, including sharp debridement, saline-moistened dressings, and nonweight-bearing regimen. Apligraf was applied directly on the ulcer and Mepitel, a porous wound contact layer, was applied as a primary non-adherent dressing. Secondary dressings were also applied. Group Discussion What types of DFUs are appropriate for Apligraf? Apligraf is appropriate for treatment of neuropathic DFUs, including large and deep ulcers (partial- and full-thickness ulcers). Ulcers at any location on the foot including the plantar surface are appropriate for Apligraf. Although Charcot disease was excluded in the clinical trials, with appropriate offloading this is not a contraindication to treatment with Apligraf. There is insufficient evidence to make recommendations regarding the use of Apligraf in patients with exposed bone or tendon, despite reports of clinical success. Frankly infected ulcers should not be treated and significant bioburden reduced, but optimization of granulation should not delay needed treatment. How should the wound be prepared? Careful and complete sharp debridement followed by irrigation is essential. This may provide for a healing milieu and reduce bacterial load. How should Apligraf be applied to the ulcer? Apligraf should be applied directly to the ulcer bed leaving a border (~5 mm) beyond the edge of the ulcer. No evidence exists to suggest differences in outcomes between different types of dressings. Detailed directions regarding the application of Apligraf are beyond the scope of this paper. What post-apligraf application measures are recommended? Adhering Apligraf is critical, which is typically achieved with Steri-Strips TM, but other methods can be utilized. Negative pressure wound therapy may augment Apligraf wound bed interaction in highly exudative wounds. It is extremely important that offloading be continued. Suggested Readings Apligraf [prescription information]. Canton MA: Organogenesis Inc; December Veves A, Falanga V, Armstrong DG, Sabolinski ML, Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2): Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging. 2007;2(1):9-98. Graftskin (Apligraf) in neuropathic diabetic foot ulcers. Wounds. 2000;12(5 suppl A):A-6A. Steinberg JS. Putting bilayered cell therapy to use. Wounds (Suppl): n 18 Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers
19 2.4 Evaluating Response to Apligraf & Reapplications Review of Evidence In the randomized controlled trial of Apligraf by Veves et al, 6 DFU patients in the treatment group could have Apligraf reapplied at 4 weekly follow-up visits following the initial application, up to 5 applications. If Apligraf appeared to cover the wound at these follow-up visits, no reapplication was performed. The average number of Apligraf applications was.9 (range: 1 to 5); 9% of patients required one application, 10% two applications, 1% three applications, 15% four applications, and 5% five applications. In the randomized controlled trial of Apligraf by Edmonds et al, 7 all patients were followed weekly for clinical assessment of the target ulcer and, if necessary, debridement of the wound. The Apligraf group could have additional monthly applications of Apligraf at week 4 and week 8 if the wound was judged to not be healing, for a maximum of applications. In the treatment group, 1 of the subjects required only 1 application, 15 received 2 applications, and 5 received applications. Therefore, in these controlled studies a majority of patients required multiple applications of Apligraf. This is consistent with findings from several small studies with different wound types that showed limited persistence. DNA evidence of Apligraf was short-lived, typically weeks to 6 weeks after application Reassess Weekly Apligraf Application Healing #1 adequately Application #2 in 1 to weeks H E Application # in 1 to weeks A Address factors interfering with healing No Wound healing progressing? L Ulcer infection Osteomyelitis Ischemia Glycemic control Inadequate offloading Poor nutrition Other factors Factors above addressed? Yes Yes Application #4 in 1 to weeks Application #5 in 1 to weeks E D Figure 10. Clinical algorithm for Apligraf management of patients with DFUs. Expert Recommendations for Optimizing Outcomes Utilizing Apligraf for Diabetic Foot Ulcers 19
Diabetic Foot Ulcer Treatment and Prevention
Diabetic Foot Ulcer Treatment and Prevention Alexander Reyzelman DPM, FACFAS Associate Professor California School of Podiatric Medicine at Samuel Merritt University Diabetic Foot Ulcers One of the most
More informationThe Georgetown Team Approach to Diabetic Limb Salvage: 2013
The Georgetown Team Approach to Diabetic Limb Salvage: 2013 John S. Steinberg, DPM FACFAS Associate Professor, Department of Plastic Surgery Georgetown University School of Medicine Disclosures: None Need
More informationSTUDY. complication of diabetes, affecting 12% to 15% of patients. during their lifetime. 1,2 Diabetic foot ulcers (DFUs) impair quality
STUDY Advanced Biological Therapies for Diabetic Foot Ulcers Robert S. Kirsner, MD, PhD; Robert Warriner, MD; Michelle Michela, MS; Laure Stasik, BA; Katherine Freeman, PhD Objective: To assess the clinical
More informationA Post-hoc Analysis of Reduction in Diabetic Foot Ulcer Size at 4 Weeks as a Predictor of Healing by 12 Weeks
A Post-hoc Analysis of Reduction in Diabetic Foot Ulcer Size at 4 Weeks as a Predictor of Healing by 12 Weeks Robert J. Snyder, DPM, CWS; Matthew Cardinal, ME; Damien M. Dauphinée, DPM, FACFAS, CWS; and
More informationAdjunctive Therapies: The Use of Skin Substitutes and Growth Factors in Venous Leg Ulceration (VLU)
Adjunctive Therapies: The Use of Skin Substitutes and Growth Factors in Venous Leg Ulceration (VLU) Sami Khan, MD FACS Associate Professor of Surgery Division of Plastic and Reconstructive Surgery SUNY-Stony
More informationDIABETES AND THE AT-RISK LOWER LIMB:
DIABETES AND THE AT-RISK LOWER LIMB: Shawn M. Cazzell Disclosure of Commercial Support: Dr. Shawn Cazzell reports the following financial relationships: Speakers Bureau: Organogenesis Grants/Research Support:
More informationThe Great Debate: Offloading Diabetic Foot Ulcers: TCC vs. CAM Walkers Gregory A Bohn, MD MAPWCA, ABPM/UHMS
The Great Debate: Offloading Diabetic Foot Ulcers: TCC vs. CAM Walkers Gregory A Bohn, MD MAPWCA, ABPM/UHMS Department of Surgery Central Michigan School of Medicine Tawas, Michigan Disclosures Medical/Scientific
More informationDiabetic/Neuropathic Foot Ulcer Assessment Guide South West Regional Wound Care Program Last Updated April 7,
Developed in collaboration with the Wound Care Champions, Wound Care Specialists, Enterostomal Nurses, and South West Regional Wound Care Program (SWRWCP) members from Long Term Care Homes, Hospitals,
More informationWOUND CARE UPDATE. -Commonly Used Skin Substitute Products For Wound. -Total Contact Casting. Jack W. Hutter DPM, FACFAS, C. ped.
WOUND CARE UPDATE -Commonly Used Skin Substitute Products For Wound Closure -Total Contact Casting Jack W. Hutter DPM, FACFAS, C. ped. Commonly Used Skin Substitute Products for Wound Closure why are they
More informationClinical Policy: EpiFix Wound Treatment
Clinical Policy: Reference Number: PA.CP.MP.140 Effective Date: 03/18 Last Review Date: 04/18 Coding Implications Revision Log Description EpiFix (MiMedx Group) is dehydrated human amniotic tissue that
More informationEmerging Use of Topical Biologics in Limb Salvage Role of Activated Collagen in Multimodality Treatment
9 th Annual New Cardiovascular Horizons New Orleans September 12, 2008 Emerging Use of Topical Biologics in Limb Salvage Role of Activated Collagen in Multimodality Treatment Gary M. Rothenberg, DPM, CDE,
More informationDiabetic Foot Ulcers. Care for Patients in All Settings
Diabetic Foot Ulcers Care for Patients in All Settings Summary This quality standard focuses on care for people who have developed or are at risk of developing a diabetic foot ulcer. The scope of the standard
More informationA New Approach To Diabetic Foot Ulcers Using Keratin Gel Technology
A New Approach To Diabetic Foot Ulcers Using Keratin Gel Technology Farheen Walid, BA, Shrunjay R. Patel, BSc, Stephanie Wu, DPM, MS Center for Lower Extremity Ambulatory Research (CLEAR), Scholl College
More informationINTEGRATED THERAPEUTIC SOLUTIONS TO MANAGE AND PREVENT DIABETIC FOOT ULCERS
INTEGRATED THERAPEUTIC SOLUTIONS TO MANAGE AND PREVENT DIABETIC FOOT ULCERS UE REMOVE EXU D R IA ER T C D TISS UIL EB ATE AN DB A REMOVE REBUILD REDUCE Cutimed Siltec Sorbact featuring DACC Technology
More informationUse of an Acellular Regenerative Tissue Matrix Over Chronic Wounds
Use of an Acellular Regenerative Tissue Matrix Over Chronic Wounds D. Heath Stacey, MD Northwest Arkansas Center for Plastic Surgery, Fayetteville, Ark Correspondence: dheathstacey@gmail.com Keywords:
More informationDefining Outcomes for Clinical Wound Research in Older Adults February 21, 2014
Defining Outcomes for Clinical Wound Research in Older Adults February 21, 214 Harold Brem, MD Professor of Surgery Stony Brook University School of Medicine Chief, Division of Wound Healing and Regenerative
More informationof :07
he diabetic foot ulcer - management and outcomes of 6 3-12-2012 11:07 The diabetic foot ulcer - management and outcomes Impaired perfusion Infection Extent and depth Condition of the ulcer Site Sensation
More informationDiabetic Foot Ulcers. Alex Khan APRN ACNS-BC MSN CWCN CFCN WCN-C. Advanced Practice Nurse / Adult Clinical Nurse Specialist
Diabetic Foot Ulcers Alex Khan APRN ACNS-BC MSN CWCN CFCN WCN-C Advanced Practice Nurse / Adult Clinical Nurse Specialist Organization of Wound Care Nurses www.woundcarenurses.org Objectives Identify Diabetic/Neuropathic
More informationJMSCR Vol 06 Issue 03 Page March 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i3.55 Thesis Paper A Prospective Comparative
More informationA comprehensive study on effect of recombinant human epidermal growth factor gel in diabetic foot ulcer
Original Research Article A comprehensive study on effect of recombinant human epidermal growth factor gel in diabetic foot ulcer S Vijayalakshmi * Associate Professor, Department of General Surgery, Govt.
More informationDisclosures. Outpatient NPWT Options Free up Hospital Beds, but Do They Work? Objectives. Clinically Effective: Does it Work?
4/16/16 Disclosures Consultant, Volcano Corporation Outpatient Options Free up Hospital Beds, but Do They Work? UCSF Vascular Symposium 16 Jonathan Labovitz, DPM Medical Director, Foot & Ankle Center Associate
More informationVenous Leg Ulcers. Care for Patients in All Settings
Venous Leg Ulcers Care for Patients in All Settings Summary This quality standard focuses on care for people who have developed or are at risk of developing a venous leg ulcer. The scope of the standard
More informationSetting The setting was a hospital. The economic study was carried out in the USA.
A cost analysis of a living skin equivalent in the treatment of diabetic foot ulcers Steinberg J, Beusterien K, Plante K, Nordin J, Chaikoff E, Arcona S, Kim J, Belletti D A Record Status This is a critical
More informationDecreased Amputation through Evidence-Based Wound Healing
The Journal of Diabetic Foot Complications Decreased Amputation through Evidence-Based Wound Healing Authors: Robert G. Frykberg, DPM, MPH 1, Edward Tierney, DPM 2, Arthur Tallis, DPM 2 The Journal of
More informationLower Extremity Wound Evaluation and Treatment
Lower Extremity Wound Evaluation and Treatment Boni-Jo Silbernagel, DPM Describe effective lower extremity wound evaluation and treatment. Discuss changes in theories of treatment in wound care and implications
More informationSmart Solutions for Serious Wounds. An advanced bilayer dermal regeneration matrix FDA approved for the treatment of diabetic foot ulcers.
Smart Solutions for Serious Wounds An advanced bilayer dermal regeneration matrix FDA approved for the treatment of diabetic foot ulcers. A New Approach to Diabetic Foot Ulcer Care Supported by Over Two
More informationCase 1. July 14, th week wound gel 3 cm x 2.5 cm = 7.5 cm². May 25, st wound gel on 290 days PI treatment 4 cm x 2.4 cm = 9.
2.5% Sodium Hyaluronate Wound Gel Study Cases Case 1 Patient with Lower Leg Ulcer Not Responding to Compression This patient was a 50-year old male patient with nonhealing right lower leg since January
More informationHyperbarics in Diabetic Wound Care. Aurel Mihai, MD & Brian Kline, MD
Hyperbarics in Diabetic Wound Care Aurel Mihai, MD & Brian Kline, MD Presentation Outline The Scope of the Problem Important Definitions Standard Wound Care Hyperbaric Oxygen as an Adjunct Diabetic Foot
More informationDiabetic/Neuropathic Foot Ulcer Assessment Guide South West Regional Wound Care Program Last Updated June 10,
Developed in collaboration with the Wound Care Champions, Wound Care Specialists, Enterostomal Nurses, and South West Regional Wound Care Program (SWRWCP) members from Long Term Care Homes, Hospitals,
More informationDEBRIDEMENT. Professor Donald G. MacLellan Executive Director Health Education & Management Innovations
DEBRIDEMENT Professor Donald G. MacLellan Executive Director Health Education & Management Innovations DEBRIDEMENT Principles - CSD Methods of Debridement Biopsy options PRINCIPLES OF WOUND MANAGEMENT
More informationEvidence-Based Rationale
Supplement to WOUNDS January 2014 Evidence-Based Rationale for Utilizing REGRANEX (becaplermin) Gel, 0.01% as an Adjunct to Standard of Care Indicated for Diabetic Foot Ulcers (DFUs) Please see Important
More informationDIABETIC ULCERS V PRESSURE ULCERS SO, WHAT DO YOU CALL IT?
DIABETIC ULCERS V PRESSURE ULCERS SO, WHAT DO YOU CALL IT? Arthur Stone, DPM Mary Sieggreen, MSN,CNS,NP,CVN Faculty Disclosure Dr. Stone has listed an affiliation with: Advisory Board Member..FXI, Inc.
More informationDressings do not heal wounds properly selected dressings enhance the body s ability to heal the wound. Progression Towards Healing
Dressings in Wound Care: They Do Matter John S. Steinberg, DPM FACFAS Associate Professor, Department of Plastic Surgery Georgetown University School of Medicine Dressings do not heal wounds properly selected
More informationWound Healing Stages
Normal Skin Wound Healing Stages Stages overlap Chronic wounds are stalled in the inflammatory phase COLLAGEN MATURATION MATRIX METALLOPROTEINASES ENDOTHELIAL CELLS EPITHELIAL CELLS MATRIX PROTEINS FIBROBLASTS
More informationYour guide to wound debridement and assessment. Michelle Greenwood. Lorraine Grothier. Lead Nurse, Tissue Viability, Walsall Healthcare NHS Trust
Your guide to wound debridement and assessment Michelle Greenwood Lead Nurse, Tissue Viability, Walsall Healthcare NHS Trust Lorraine Grothier Clinical Nurse Specialist, Tissue Viability, Central Essex
More informationFrequency of Debridements and Time to Heal A Retrospective Cohort Study of Wounds
Research Original Investigation Frequency of Debridements and Time to Heal A Retrospective Cohort Study of 312 744 Wounds James R. Wilcox, RN; Marissa J. Carter, PhD, MA; Scott Covington, MD IMPORTANCE
More informationWound, Ostomy and Continence Nursing Certification Board (WOCNCB) Certified Foot Care Nurse (CFCN) Detailed Content Outline
Wound, Ostomy and Continence Nursing Certification Board (WOCNCB) Certified Foot Care Nurse (CFCN) Detailed Content Outline Description Domain I: Assessment and Care Planning 010000 40 Task 1: Obtain focused
More informationMean percent reduction in ulcer area from baseline at six weeks 62 % SANTYL Ointment + supportive care* + sharp debridement 1 (P<0.
Evaluating two common adjuncts to sharp debridement in the treatment of diabetic foot ulcers Mean percent reduction in ulcer area from baseline at six weeks 62 % 40 % SANTYL Ointment + supportive care*
More informationTopical Oxygen Wound Therapy (MEDICAID)
Topical Oxygen Wound Therapy (MEDICAID) Last Review Date: September 8, 2017 Number: MG.MM.DM.15C8v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or
More informationRegenerative Tissue Matrix in Treatment of Wounds
Regenerative Tissue Matrix in Treatment of Wounds Learning Objectives Differentiate between reparative and regenerative healing Review surgical techniques for applying a regenerative tissue scaffold to
More informationULCERS 1/12/ million diabetics in the US (2012) Reamputation Rate 26.7% at 1 year 48.3% at 3 years 60.7% at 5 years
Jay Christensen D.P.M Advanced Foot and Ankle of Wisconsin 2-4% of the population at any given time will have ulcers 0.06-0.20% of the total population Average age of patients 70 years increased as more
More informationPrediction of healing for post-operative diabetic foot wounds based on early wound area progression
Diabetes Care Publish Ahead of Print, published online October 12, 2007 Prediction of healing for post-operative diabetic foot wounds based on early wound area progression Lawrence A Lavery, DPM, MPH 1
More informationMy Diabetic Patient Has No Pulses; What Should I Do?
Emily Malgor, MD Assistant Professor of Surgery University of Oklahoma, Oklahoma City My Diabetic Patient Has No Pulses; What Should I Do? There are no disclosures. Background Diabetes affects 387 million
More information2008 American Medical Association and National Committee for Quality Assurance. All Rights Reserved. CPT Copyright 2007 American Medical Association
Chronic Wound Care ASPS #1: Use of wound surface culture technique in patients with chronic skin ulcers (overuse measure) This measure may be used as an Accountability measure Clinical Performance Measure
More informationOriginal Article Tissue engineered skin for diabetic foot ulcers: a meta-analysis
Int J Clin Exp Med 2015;8(10):18191-18196 www.ijcem.com /ISSN:1940-5901/IJCEM0014309 Original Article Tissue engineered skin for diabetic foot ulcers: a meta-analysis Xuedong Li 1, Geliang Xu 2, Jianqiu
More informationCLI Therapy- LINCed Multi disciplinary discussions on CLI
CLI Therapy- LINCed Multi disciplinary discussions on CLI Critical limb ischemia and managing the infected wound Michiel Schreve North West Clinics Alkmaar, The Netherlands Disclosure Speaker name: Michiel
More informationStatistics on DM and DFU risk
Disclosure NOTHING Statistics on DM and DFU risk National Institute of Diabetes Digestive & Kidney Diseases: As of September 2011 an estimated 16 million Americans are known to have diabetes, with many
More informationAWMA MODULE ACCREDITATION. Module Five: The High Risk Foot (Including the Diabetic Foot)
AWMA MODULE ACCREDITATION Module Five: The High Risk Foot (Including the Diabetic Foot) Introduction - The Australian Wound Management Association Education & Professional Development Sub Committee-(AWMA
More informationALLIANCE OF WOUND CARE STAKEHOLDERS. Palmetto GBA Public Meeting Draft LCD on Application of Skin Substitutes (DL36466) October 13, 2015
ALLIANCE OF WOUND CARE STAKEHOLDERS Palmetto GBA Public Meeting Draft LCD on Application of Skin Substitutes (DL36466) October 13, 2015 1 ALLIANCE OF WOUND CARE Who is the Alliance? STAKEHOLDERS A non-profit
More informationClinical and Economic Benefits of Healing Diabetic Foot Ulcers With a Rigid Total Contact Cast
Clinical and Economic Benefits of Healing Diabetic Foot Ulcers With a Rigid Total Contact Cast Shishir Shah, DO Sub-optimal offloading results in delayed healing and thus directs the clinician into considering
More informationA one year cross sectional study on role of Wagner s classification in predicting the outcome in diabetic foot ulcer patients
International Surgery Journal Praveena DL et al. Int Surg J. 2018 Jul;5(7):2537-2542 http://www.ijsurgery.com pissn 2349-3305 eissn 2349-2902 Original Research Article DOI: http://dx.doi.org/10.18203/2349-2902.isj20182769
More informationCLINICAL EVIDENCE Partial and Deep Partial Burns
CLINICAL EVIDENCE Partial and Deep Partial Burns Endoform helps to improve re-epithelialization after burn injuries Endoform helps to facilitate tissue granulation and epithelialization in partial and
More informationLimb Salvage in Diabetic Ischemic Foot. Kritaya Kritayakirana, MD, FACS Assistant Professor Chulalongkorn University April 30, 2017
Limb Salvage in Diabetic Ischemic Foot Kritaya Kritayakirana, MD, FACS Assistant Professor Chulalongkorn University April 30, 2017 Case Male 67 years old Underlying DM, HTN, TVD Present with gangrene
More informationDiabetic Foot-Evidence that counts
Bahrain Medical Bulletin, Vol. 28, No. 3, September 2006 Family Physician Corner Diabetic Foot-Evidence that counts Abeer Al-Saweer, MD* Evidence-based medicine has systemized the medical thinking in each
More informationTotal Contact Cast System
Total Contact Cast System Instructions for Use Products Included in Cutimed Off-Loader Select kit Qty Cutimed Cavity Sterile 1 ea. Cutisorb Cotton Gauze 2" x 2" 4 ea. Delta-Lite Conformable Fiberglass
More informationThe Use of the. in Clinical Practice
The Use of the SNAP Therapy System in Clinical Practice It s an ultraportable, mechanically-powered disposable NPWT. By Animesh Bhatia, DPM, CWS This article is written exclusively for PM and appears courtesy
More informationQuicker application Great comfort. TCC wound healing rate 1,2. Advancing the Gold Standard of Care. ESSENTIAL TO HEALTH
Quicker application Great comfort GOLD STANDARD OF CARE TCC wound healing rate 1,2 Advancing the Gold Standard of Care. ESSENTIAL TO HEALTH Why risk any other treatment method? Potential consequences for
More informationEquine Pericardium Collagen Wound Dressing in the Treatment of the Neuropathic Diabetic Foot Wound
ORIGINAL ARTICLES Equine Pericardium Collagen Wound Dressing in the Treatment of the Neuropathic Diabetic Foot Wound A Pilot Study John G. Fleischli, DPM* Terese J. Laughlin, DPM* Jeffery W. Fleischli,
More informationQUICK GUIDE SNAP THERAPY SYSTEM
QUICK GUIDE SNAP THERAPY SYSTEM Clinical Pathway to SNAP System Full holistic assessment of patient and wound Is the wound type indicated for NPWT use without contraindications 1? SNAP System is indicated
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationClinical assessment of diabetic foot in 5 minutes
Clinical assessment of diabetic foot in 5 minutes Assoc. Prof. N. Tentolouris, MD 1 st Department of Propaedeutic Internal Medicine Medical School Laiko General Hospital Leading Innovative Vascular Education
More informationCost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers Sibbald R G, Torrance G, Hux M, Attard C, Milkovich N
Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers Sibbald R G, Torrance G, Hux M, Attard C, Milkovich N Record Status This is a critical abstract of an economic evaluation
More informationAcute and Chronic WOUND ASSESSMENT. Wound Assessment OBJECTIVES ITEMS TO CONSIDER
WOUND ASSESSMENT Acute and Chronic OBJECTIVES Discuss classification systems and testing methods for pressure ulcers, venous, arterial and diabetic wounds List at least five items to be assessed and documented
More informationEquine Pericardium as a Biological Covering for the Treatment of Diabetic Foot Wounds
ORIGINAL ARTICLES Equine Pericardium as a Biological Covering for the Treatment of Diabetic Foot Wounds A Prospective Study Jeffery H. Alexander, DPM* David A. Yeager, DPM Dean S. Stern, DPM* Carlo A.
More informationWound Management. E. Foy White-Chu, MD, CWSP
Wound Management E. Foy White-Chu, MD, CWSP E. Foy White-Chu, MD, CWSP Assistant Professor, OHSU Wound Medical Director, VAPORHCS List the Four Principles of Wound Bed Preparation Determine safe debridement
More informationDisclosures for Tarik Alam. Wound Bed Preparation. Wound Prognosis. Session Objectives. Debridement 4/26/2015
Disclosures for Tarik Alam Challenges in Managing Bioburden and Devitalized Tissue Tarik Alam RN, BScN, ET, MClSc(WH) Enterostomal Therapy Nurse tarikalam@hotmail.com Clinical Affairs Manager for Hollister
More informationEVALUATION OF THE VASCULAR STATUS OF DIABETIC WOUNDS Travis Littman, MD NorthWest Surgical Specialists
EVALUATION OF THE VASCULAR STATUS OF DIABETIC WOUNDS Travis Littman, MD NorthWest Surgical Specialists Nothing To Disclosure DISCLOSURES I have no outside conflicts of interest, financial incentives, or
More informationAuthors' objectives To assess the value of treatments for foot ulcers in patients with Type 2 diabetes mellitus.
A systematic review of foot ulcer in patients with Type 2 diabetes mellitus - II: treatment Mason J, O'Keeffe C, Hutchinson A, McIntosh A, Young R, Booth A Authors' objectives To assess the value of treatments
More informationDiabetic Foot Ulcer. A Complete Solution. Therapy Approach with Adapted Products
Diabetic Foot Ulcer A Complete Solution Therapy Approach with Adapted Products A Complete Solution for Diabetic Foot Ulcers This booklet focuses on the recommended treatment of diabetic foot ulcers. Diabetes
More informationEmerging Evidence On Advanced Wound Care For Diabetic Foot Ulcerations
ABH_Supp:Layout 1 2/8/11 11:35 AM Page 2 Supplement to Podiatry Today Emerging Evidence On Advanced Wound Care For Diabetic Foot Ulcerations Applying evidence-based medicine and the standard of care to
More informationClinical Policy Title: Debridement of diabetic foot ulcers
Clinical Policy Title: Debridement of diabetic foot ulcers Clinical Policy Number: CCP.1200 Effective Date: January 1, 2016 Initial Review Date: October 19, 2015 Most Recent Review Date: October 2, 2018
More informationNew Strategies to Improve Assessment, Documentation and Prevention of Pressure Injuries
New Strategies to Improve Assessment, Documentation and Prevention of Pressure Injuries Janet Cuddigan, PhD, RN, CWCN, FAAN Professor, UNMC College of Nursing Omaha, NE Focus of this Presentation New developments
More informationHyperbaric Oxygen Utilization in Wound Care
Hyperbaric Oxygen Utilization in Wound Care Robert Barnes, MD, CWS Hyperbaric Center Sacred Heart Medical Center Riverbend Springfield, Oregon No relevant disclosures Diabetes and lower extremity wounds
More informationOxygen is required for normal cellular
Article The role of topical oxygen therapy in the management of diabetic foot ulcer s in Scotland: round table recommendations Citation: Stang D, Young M, Wilson D et al (18) The role of topical oxygen
More informationDIABETIC FOOT RISK CLASSIFICATION IN A TERTIARY CARE TEACHING HOSPITAL OF PESHAWAR
ORIGINAL ARTICLE DIABETIC FOOT RISK CLASSIFICATION IN A TERTIARY CARE TEACHING HOSPITAL OF PESHAWAR Ghulam Shabbier, Said Amin, Ishaq Khattak, Sadeeq-ur-Rehman Department of Medicine Khyber Teaching Hospital
More informationWound Care Evaluation by Kris Dalseg MS PT CWS CLT
Wound Care Evaluation by Kris Dalseg MS PT CWS CLT This document is intended to describe a standard wound care evaluation for healthcare practitioners. In healthcare, all aspects of our treatment have
More informationEugene J Nuccio 1 *, Lawrence A Lavery 2 and Sung-Joon Min 1
Diabetes Management Innovative Treatment of Chronic Diabetic Foot Ulcer in a Controlled Randomized Clinical Trial Produces Fewer Adverse Events, Faster Wound Closure, and Lower Costs Eugene J Nuccio 1
More informationEmbrace the Call to Wound Prevention and Care
CONCLUSION Embrace the Call to Wound Prevention and Care A challenging career Be part of an interprofessional team Help patients, families, communities Commit to lifelong learning To cure occasionally,
More informationA comprehensive study on effect of collagen dressing in diabetic foot ulcer
Original Research Article A comprehensive study on effect of collagen dressing in diabetic foot ulcer Sivakumar 1, S. Shanmugam 2* 1 Associate Professor, 2 Senior Assistant Professor Department of General
More informationFluorescence Angiography in Limb Salvage
Fluorescence Angiography in Limb Salvage Ryan H. Fitzgerald, DPM, FACFAS Associate Professor of Surgery-University Of South Carolina School of Medicine, Greenville Etiology of Lower extremity wounds Neuropathy
More informationSurgical Off-loading. Reiber et al Goals of Diabetic Foot Surgery 4/28/2012. The most common causal pathway to a diabetic foot ulceration
Reiber et al. 1999 Surgical Off-loading The most common causal pathway to a diabetic foot ulceration Alex Reyzelman DPM Associate Professor California School of Podiatric Medicine at Samuel Merritt University
More informationAGONY FEET. The. of the. Prevention and management of diabetic foot ulcers
The AGONY of the FEET Prevention and management of diabetic foot ulcers By Margaret Falconio-West, BSN, rn, APN/CNS, CWOCN, DAPWCA Nearly 25 percent of people with diabetes will develop a diabetic foot
More informationo Venous edema o Stasis ulcers o Varicose veins (not including spider veins) o Lipodermatosclerosis
Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018 Effective for dates of service on or after July 1, 2018, wound care equipment and supply benefits will change for Texas
More informationEconomic Considerations of Amputation Prevention
Economic Considerations of Amputation Prevention Adam Landsman, DPM, PhD Assistant Professor of Surgery Harvard Medical School Chief, Division of Podiatric Surgery Cambridge Health Alliance Cambridge,
More informationIncreased pressures at
Surgical Off-loading of Plantar Hallux Ulcerations These approaches can be used to treat DFUs. By Adam R. Johnson, DPM Increased pressures at the plantar aspect of the hallux leading to chronic hyperkeratosis
More informationChallenging wounds, improving outcomes. Treatment of complex diabetic foot wounds using topical oxygen therapy
Challenging wounds, improving outcomes Treatment of complex diabetic foot wounds using topical oxygen therapy A FOREWORD The essential role of oxygen in wound healing is well documented, and recent developments
More informationFirst Coast Service Options (FCSO) Medicare Policy Primer
First Coast Service Options (FCSO) Medicare Policy Primer Medicare Jurisdiction (JN) Florida, Puerto Rico and U.S. Virgin Islands Application of Skin Substitute Grafts for the treatment of DFU and VLU
More informationMonitoring Prevent. Can Temperature. DFUs
Can Temperature Monitoring Prevent DFUs Alexander Reyzelman DPM Associate Professor, California School of Podiatric Medicine at Samuel Merritt University Oakland, CA Co-Director, UCSF Center for Limb Preservation
More informationDue to Perimed s commitment to continuous improvement of our products, all specifications are subject to change without notice.
A summary Disclaimer The information contained in this document is intended to provide general information only. It is not intended to be, nor does it constitute, medical advice. Under no circumstances
More information4/6/2018. Kimberly Jamison, MD, FACP, FAPWCA
Kimberly Jamison, MD, FACP, FAPWCA 1 From 1980 to 2011 the number of Americans with diagnosed diabetes more than tripled An estimated 12.7% of Americans with diabetes develop a foot ulcer 60% of all lower
More informationNovitas Medicare Policy Primer
Novitas Medicare Policy Primer Medicare Jurisdiction (JL and JH) AR, CO, LA, MS, NM, OK, TX, DC, DE, MD, NJ, & PA Counties of Arlington and Fairfax in Virginia and the city of Alexandria in Virginia Application
More informationClinical Review Criteria
Clinical Review Criteria Autologous Platelet Derived Wound Healing Factors for Treatment of: Non Healing Cutaneous Wounds (Procuren) Non-Healing Fractures and the Associated GEM 21STM Device Platelet Rich
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationThe Risk. Background / Bias. Integrating Wound Care into a Limb Preservation Initiative 4/24/2009
Stimulating Wound Granulation: Advances in NPWT and other Measures (Wound Bed Preparation) Charles Andersen MD, FACS, FAPWCA Clinical Prof of Surgery UW, USUHS Chief Vascular/Endovascular/ Limb Preservation
More informationDISCLOSURE STATEMENT 10/8/ BASIC OF ELEMENTS OF LIMB SALVAGE MANAGEMENT
LI MB SALVAGE MANAGEMENT October 11, 2018 DISCLOSURE STATEMENT My opinions do not represent the VA s opinions in regards to product preference No specific proprietary data from the VA has been included
More informationHemostasis Inflammatory Phase Proliferative/rebuilding Phase Maturation Phase
The presenters are staff members of the CHI Health St. Elizabeth Burn and Wound Center. Many of the products discussed are used in our current practice but we have no conflict of interest to disclose.
More informationSNAP THERAPY SYSTEM MONOGRAPH
SNAP THERAPY SYSTEM MONOGRAPH Table of Contents Introduction...3 SNAP System Components Literature Review...4 Clinical Evidence Supporting SNAP System... 7 Technology for SNAP System.........................................11
More informationA Pilot Study of Oxygen Therapy for Acute Leg Ulcers
A Pilot Study of Oxygen Therapy for Acute Leg Ulcers Background: The concept of increasing the oxygen concentration in healing wounds developed originally with hyperbaric oxygen therapy and from the fact
More information